The University of Chicago Header Logo

Connection

Derek Wainwright to Animals

Back to Details
This is a "connection" page, showing publications Derek Wainwright has written about Animals.
Derek Wainwright
Connection Strength
0.991
Animals
  1. Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence. Clin Cancer Res. 2023 12 01; 29(23):4973-4989.
    View in: PubMed
    Score: 0.058
  2. Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for Glioblastoma. J Med Chem. 2022 12 08; 65(23):15642-15662.
    View in: PubMed
    Score: 0.054
  3. Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies. Front Immunol. 2020; 11:1185.
    View in: PubMed
    Score: 0.046
  4. Quantification of IDO1 enzyme activity in normal and malignant tissues. Methods Enzymol. 2019; 629:235-256.
    View in: PubMed
    Score: 0.043
  5. IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. Clin Cancer Res. 2018 06 01; 24(11):2559-2573.
    View in: PubMed
    Score: 0.039
  6. IDO1 in cancer: a Gemini of immune checkpoints. Cell Mol Immunol. 2018 May; 15(5):447-457.
    View in: PubMed
    Score: 0.039
  7. The Boosting Potential of Bacteria in Cancer Immunotherapy. Trends Mol Med. 2017 07; 23(7):580-582.
    View in: PubMed
    Score: 0.037
  8. Therapeutic Hypothesis Testing With Rodent Brain Tumor Models. Neurotherapeutics. 2017 04; 14(2):385-392.
    View in: PubMed
    Score: 0.037
  9. Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma. Brain Behav Immun. 2017 May; 62:24-29.
    View in: PubMed
    Score: 0.036
  10. Advanced age negatively impacts survival in an experimental brain tumor model. Neurosci Lett. 2016 Sep 06; 630:203-208.
    View in: PubMed
    Score: 0.035
  11. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy. Clin Cancer Res. 2015 Dec 15; 21(24):5427-33.
    View in: PubMed
    Score: 0.033
  12. The role of IDO in brain tumor immunotherapy. J Neurooncol. 2015 Jul; 123(3):395-403.
    View in: PubMed
    Score: 0.031
  13. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res. 2014 Oct 15; 20(20):5290-301.
    View in: PubMed
    Score: 0.030
  14. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res. 2012 Nov 15; 18(22):6110-21.
    View in: PubMed
    Score: 0.027
  15. Recent developments on immunotherapy for brain cancer. Expert Opin Emerg Drugs. 2012 Jun; 17(2):181-202.
    View in: PubMed
    Score: 0.026
  16. Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors. Neuro Oncol. 2011 Dec; 13(12):1308-23.
    View in: PubMed
    Score: 0.025
  17. The expression of BST2 in human and experimental mouse brain tumors. Exp Mol Pathol. 2011 Aug; 91(1):440-6.
    View in: PubMed
    Score: 0.024
  18. The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human glioma. PLoS One. 2010 Oct 23; 5(10):e15390.
    View in: PubMed
    Score: 0.023
  19. Toll-like receptor 2 and facial motoneuron survival after facial nerve axotomy. Neurosci Lett. 2010 Feb 26; 471(1):10-4.
    View in: PubMed
    Score: 0.022
  20. Effects of facial nerve axotomy on Th2- and Th1-associated chemokine expression in the facial motor nucleus of wild-type and presymptomatic mSOD1 mice. J Neuroimmunol. 2009 Nov 30; 216(1-2):66-75.
    View in: PubMed
    Score: 0.022
  21. NKG2C/KLRC2 tumor cell expression enhances immunotherapeutic efficacy against glioblastoma. J Immunother Cancer. 2024 Aug 30; 12(8).
    View in: PubMed
    Score: 0.015
  22. Aging amplifies a gut microbiota immunogenic signature linked to heightened inflammation. Aging Cell. 2024 Aug; 23(8):e14190.
    View in: PubMed
    Score: 0.015
  23. Lactate dehydrogenase A regulates tumor-macrophage symbiosis to promote glioblastoma progression. Nat Commun. 2024 Mar 05; 15(1):1987.
    View in: PubMed
    Score: 0.015
  24. Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry. J Immunother Cancer. 2022 07; 10(7).
    View in: PubMed
    Score: 0.013
  25. Circadian Regulator CLOCK Drives Immunosuppression in Glioblastoma. Cancer Immunol Res. 2022 06 03; 10(6):770-784.
    View in: PubMed
    Score: 0.013
  26. Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. Cell Rep. 2021 11 02; 37(5):109957.
    View in: PubMed
    Score: 0.013
  27. Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma. Clin Cancer Res. 2021 12 01; 27(23):6514-6528.
    View in: PubMed
    Score: 0.012
  28. NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol. 2021 01 06; 14(1):7.
    View in: PubMed
    Score: 0.012
  29. Targeting CD73 to augment cancer immunotherapy. Curr Opin Pharmacol. 2020 08; 53:66-76.
    View in: PubMed
    Score: 0.012
  30. Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. Clin Cancer Res. 2020 10 01; 26(19):5232-5245.
    View in: PubMed
    Score: 0.011
  31. Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy. J Hematol Oncol. 2020 06 09; 13(1):74.
    View in: PubMed
    Score: 0.011
  32. Receptor tyrosine kinase signaling regulates different modes of Groucho-dependent control of Dorsal. Curr Biol. 2000 Jan 13; 10(1):51-4.
    View in: PubMed
    Score: 0.011
  33. CD73: an emerging checkpoint for cancer immunotherapy. Immunotherapy. 2019 08; 11(11):983-997.
    View in: PubMed
    Score: 0.011
  34. A Dendritic Cell-Targeted Adenoviral Vector Facilitates Adaptive Immune Response Against Human Glioma Antigen (CMV-IE) and Prolongs Survival in a Human Glioma Tumor Model. Neurotherapeutics. 2018 10; 15(4):1127-1138.
    View in: PubMed
    Score: 0.010
  35. Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer. J Immunother Cancer. 2017 09 19; 5(1):77.
    View in: PubMed
    Score: 0.009
  36. Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival. Clin Cancer Res. 2017 Nov 01; 23(21):6650-6660.
    View in: PubMed
    Score: 0.009
  37. Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. Ann Oncol. 2017 01 01; 28(1):44-56.
    View in: PubMed
    Score: 0.009
  38. CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells. Cancer Res. 2016 10 01; 76(19):5671-5682.
    View in: PubMed
    Score: 0.009
  39. Updates from the Neuro-Oncology Section of the 2015 American Neurological Association Annual Meeting. Future Oncol. 2016 Jan; 12(2):143-7.
    View in: PubMed
    Score: 0.008
  40. Dendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant Glioma. J Immunol. 2015 Jul 01; 195(1):367-76.
    View in: PubMed
    Score: 0.008
  41. Blood-brain barrier permeable gold nanoparticles: an efficient delivery platform for enhanced malignant glioma therapy and imaging. Small. 2014 Dec 29; 10(24):5137-50.
    View in: PubMed
    Score: 0.008
  42. Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma. Cancer Gene Ther. 2014 Jan; 21(1):38-44.
    View in: PubMed
    Score: 0.007
  43. Heme oxygenase-1 protects regulatory T cells from hypoxia-induced cellular stress in an experimental mouse brain tumor model. J Neuroimmunol. 2014 Jan 15; 266(1-2):33-42.
    View in: PubMed
    Score: 0.007
  44. Fibrin-binding, peptide amphiphile micelles for targeting glioblastoma. Biomaterials. 2014 Jan; 35(4):1249-56.
    View in: PubMed
    Score: 0.007
  45. Nanoparticle-programmed self-destructive neural stem cells for glioblastoma targeting and therapy. Small. 2013 Dec 20; 9(24):4123-9.
    View in: PubMed
    Score: 0.007
  46. Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor a2. J Biol Chem. 2012 Aug 31; 287(36):30215-27.
    View in: PubMed
    Score: 0.007
  47. CD4+ T cell-mediated neuroprotection is independent of T cell-derived BDNF in a mouse facial nerve axotomy model. Brain Behav Immun. 2012 Aug; 26(6):886-90.
    View in: PubMed
    Score: 0.006
  48. The challenge for gene therapy: innate immune response to adenoviruses. Oncotarget. 2011 Mar; 2(3):113-21.
    View in: PubMed
    Score: 0.006
  49. Short hairpin RNA-mediated fibronectin knockdown delays tumor growth in a mouse glioma model. Neoplasia. 2010 Oct; 12(10):837-47.
    View in: PubMed
    Score: 0.006
  50. IL-10 within the CNS is necessary for CD4+ T cells to mediate neuroprotection. Brain Behav Immun. 2011 Jul; 25(5):820-9.
    View in: PubMed
    Score: 0.006
  51. Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-adenoviral immune response in the cotton rat model. Mol Ther. 2010 Oct; 18(10):1846-56.
    View in: PubMed
    Score: 0.006
  52. Phenotype of CD4+ T cell subsets that develop following mouse facial nerve axotomy. Brain Behav Immun. 2008 May; 22(4):528-37.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.